We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00800852
First Posted: December 2, 2008
Last Update Posted: December 2, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Samsung Medical Center
  Purpose

The inflammatory process is involved in the pathogenesis of obesity. Prader-Willi syndrome (PWS) is a genetic model of syndromic obesity. Adiponectin is an adipokine with potent anti-inflammatory properties, and its effect is mediated through adiponectin receptors 1 (adipoR1) and 2 (adipoR2).

Objective of this study is to compare the expression of adipoR1, adipoR2, and adiponectin in peripheral blood mononuclear cells (PBMCs) in PWS children and obese control and to correlate receptor expression with insulin sensitivity and obesity-related parameters.


Condition
Obesity Prader-Willi Syndrome

Study Type: Observational
Official Title: Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome

Resource links provided by NLM:


Further study details as provided by Samsung Medical Center:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Fourteen children with PWS and control subjects
Criteria

Inclusion Criteria:

  • children with Prader-willi syndrome
  • children with simple obesity

Exclusion Criteria:

  • subjects with diabetes mellitus (fasting plasma glucose > 126 mg/dL with a 2-h oral glucose tolerance test value of >200 mg/dl)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00800852


Sponsors and Collaborators
Samsung Medical Center
Investigators
Principal Investigator: Don-Kyu Jin, M.D. Samsung Medical Center, Sungkyunkwan Uiversity School of Medicine
  More Information

Responsible Party: Dong-Kyu Jin, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT00800852     History of Changes
Other Study ID Numbers: 2008-10-040
First Submitted: November 30, 2008
First Posted: December 2, 2008
Last Update Posted: December 2, 2008
Last Verified: November 2008

Keywords provided by Samsung Medical Center:
adiponectin
adiponectin receptor
Prader-Willi syndrome

Additional relevant MeSH terms:
Syndrome
Prader-Willi Syndrome
Disease
Pathologic Processes
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Obesity
Overnutrition
Nutrition Disorders